koto_feja/E+ via Getty Images
Cancer drug maker Mersana Therapeutics (NASDAQ:MRSN) hit a 52-week low on Friday after it shared early clinical results from a Phase 1 trial for its lead candidate emiltatug ledatotin (Emi-Le) in solid tumors.
Based on the December 13 data cut, Mersana (